Core Viewpoint - 康龙化成 reported a revenue of 14.095 billion RMB for the year ending December 31, 2025, representing a year-on-year growth of 14.82%, while the net profit attributable to shareholders decreased by 7.2% to 1.664 billion RMB [1] Group 1: Financial Performance - The company announced a proposed final dividend of 2.0 RMB per 10 shares (tax included) for the year ending December 31, 2025 [1] - The revenue growth of 14.82% indicates strong operational performance despite the decline in net profit [1] - The new signed orders increased by over 14% year-on-year, indicating a positive trend in business development [1] Group 2: Strategic Initiatives - The company emphasizes a customer-centric service philosophy and leverages an integrated service platform to meet diverse global client needs [1] - Significant achievements were noted in expanding the client base, particularly with large pharmaceutical companies [1] - The company is actively implementing market strategies tailored to the Chinese market, contributing to rapid growth in client business [1] Group 3: Future Outlook - The company anticipates a revenue growth of 12% to 18% for the year 2026 based on new signed orders and business trends [1] - The company maintains industry leadership in small molecule fields while also achieving rapid development in new molecular type projects [1]

2025年是中远海发厚植航运基因、释放创新价值，为"十四五"圆满收官、"十五五"开篇蓄势聚能的关键 年。公司着力增强"产、融、投"核心功能，加快培育和发展航运产融新质生产力，以价值创造切实回报 股东，在迈向可持续发展征程中践行公司的坚定承诺。 格隆汇3月31日丨中远海发(02866.HK)公告，2025年，公司实现营业收益人民币249.85亿元，除税前溢 利人民币20.67亿元，同比增长33.57%，母公司拥有人应占持续经营活动溢利人民币16.09亿元，同比增 长9.31%，基本每股盈利为人民币0.1214元。公司已派发2025年中期股息每股人民币0.022元，董事会建 议派发2025年末期股息每股人民币0.015元，2025年度合计派发股息每股人民币0.037元。 ...

Core Viewpoint - 康龙化成 reported a revenue of 14.095 billion RMB for the year ending December 31, 2025, representing a year-on-year growth of 14.82%, while the net profit attributable to shareholders decreased by 7.2% to 1.664 billion RMB [1] Group 1: Financial Performance - The company's revenue for the fiscal year was 14.095 billion RMB, showing a growth of 14.82% compared to the previous year [1] - The net profit attributable to shareholders was 1.664 billion RMB, which is a decrease of 7.2% year-on-year [1] - The board proposed a final dividend of 2.0 RMB per 10 shares (before tax) for the year ending December 31, 2025 [1] Group 2: Strategic Initiatives - The company is deepening its customer-centric service philosophy and leveraging a fully integrated service platform to meet diverse global client needs [1] - Significant achievements were noted in expanding strategic customer relationships, particularly with large pharmaceutical companies [1] - The company is actively implementing market strategies tailored to the Chinese market, resulting in rapid growth in client business [1] Group 3: Future Outlook - The company expects a year-on-year growth of over 14% in new signed orders for 2025 [1] - Based on new orders and business trends, the company anticipates a revenue growth of 12% to 18% for the year 2026 [1]

Core Viewpoint - China Shenhua (01088) reported a decline in revenue and profit for the year 2025, primarily due to decreased coal sales volume and prices, as well as reduced electricity sales [1] Group 1: Financial Performance - Revenue for 2025 was 294.916 billion yuan, a year-on-year decrease of 13.2% [1] - Profit attributable to shareholders was approximately 54.218 billion yuan, down 8.9% year-on-year [1] - Basic earnings per share were 2.729 yuan, with a final cash dividend of 1.03 yuan per share [1] Group 2: Revenue Decline Factors - The decline in revenue was mainly due to a 6.4% decrease in coal sales volume and a 12.1% drop in average sales price, leading to reduced coal sales revenue [1] - Electricity sales volume and average sales price fell by 3.9% and 4.0% respectively, resulting in a decrease in electricity sales revenue [1]

Group 1 - The company, Kanglong Chemical (SZ 300759), announced on March 30 that it will hold the 19th meeting of the third board of directors on the same day to review a proposal for using part of its own funds to purchase financial products [1] - The investment aims to improve the efficiency of fund utilization and rationally use idle self-owned funds, ensuring that normal operations of the company and its subsidiaries are not affected [1] - The total investment amount is proposed to be no more than 5 billion RMB, with the idle self-owned funds being available for cyclical use during the investment period [1]

Group 1 - The company China Shenhua (SH 601088) announced the convening of its sixth board of directors' 17th meeting on March 30, 2026, in Beijing, which will be held both in-person and via communication methods [1] - The meeting will review the proposal regarding the financial report for the fiscal year 2025 [1]

Core Viewpoint - Kanglong Chemical (03759) reported a revenue of 14.095 billion RMB for the year ending December 31, 2025, representing a year-on-year growth of 14.8% [1] Financial Performance - The profit attributable to the company's shareholders was 1.664 billion RMB, a decrease of 7.2% year-on-year [1] - Basic earnings per share were 0.9443 RMB, with a proposed final dividend of 2.0 RMB per 10 shares (tax included) [1] Laboratory Services Segment - Revenue from laboratory services reached 8.1589 billion RMB, an increase of 15.8% compared to the previous year [1] - The gross margin for the laboratory services segment was 44.7%, up by 0.3 percentage points year-on-year [1] - New orders in this segment grew by approximately 12% year-on-year [1] Strategic Developments - In 2025, the company expanded multiple strategic partnerships and achieved breakthroughs in large collaborative projects [1] - The company leveraged its academic advantages and technical accumulation to achieve rapid development in new molecular drug research services [1] Workforce and Global Impact - As of December 31, 2025, the laboratory services workforce comprised 11,776 employees, including over 7,100 laboratory chemists, positioning the company as a leader in scale and experience in laboratory chemical services globally [1] - The laboratory services team participated in 887 global innovative drug discovery projects during the reporting period [1]

Core Viewpoint - China Galaxy Securities reported a record net profit of 12.52 billion yuan for 2025, marking a year-on-year increase of 24.81%, driven by strong growth across various business segments [2]. Business Performance - Total assets of China Galaxy Securities reached 855.75 billion yuan by the end of 2025, reflecting a 16.04% increase from the end of 2024, maintaining a strong position within the top five in the industry [3]. - Wealth management business generated revenue of 13.47 billion yuan, up 28.36% year-on-year; investment banking revenue was 585 million yuan, increasing by 22.18%; institutional business revenue surged by 508.2% to 1.74 billion yuan; international business revenue reached 2.57 billion yuan, growing by 18.23%; trading business revenue was 7.03 billion yuan, up 10.76%; and integrated business revenue was 2.77 billion yuan, increasing by 11.16% [3][4]. - The company achieved record high revenues across wealth management, investment banking, trading, institutional, and international business segments in 2025 [3]. Institutional Business Growth - The institutional business revenue saw a remarkable increase of 508.2% year-on-year, with the number of covered institutional clients rising to 8,040, an increase of over 1,000 clients from the previous year [4]. - The scale of the PB (Private Banking) business reached 481.4 billion yuan, growing by 38.3%, with trading volume for equity transactions amounting to 5.45 trillion yuan, a year-on-year increase of 52.1% [4]. International Investment Banking Expansion - China Galaxy Securities' bond underwriting scale reached 682.58 billion yuan in 2025, a 37.3% increase, ranking 6th in the industry, with local government bond underwriting at 433.33 billion yuan, ranking 5th [5]. - In equity business, the company completed three major asset restructuring projects with a total transaction value of 19.47 billion yuan, ranking 7th in the industry [5]. - The company ranked in the top 10 for Hong Kong IPO sponsorships for the first time and was 4th among Chinese brokers in terms of project participation [5][6]. International Market Activities - China Galaxy Securities completed 71 equity and bond financing transactions overseas, totaling 4.7 billion Singapore dollars, including significant projects in Malaysia and Singapore [5][6]. - The company launched its first public fund and made strides in FICC and cross-border business, including the first gold transaction [6].

Core Viewpoint - The company, Jinju Group, plans to enhance its financing efficiency and optimize its debt structure by applying for the qualification to issue various debt financing instruments in the interbank market, with a total issuance limit of up to 40 billion yuan [1][2]. Group 1 - The company has approved a proposal to register and issue debt financing tools at the 20th meeting of the 7th Board of Directors held on March 30, 2026 [1]. - The registration project includes the qualification for unified registration of various non-financial corporate debt financing instruments (DFI) [1]. - The types of instruments to be issued include but are not limited to super short-term financing bills, short-term financing bills, medium-term notes, perpetual medium-term notes, targeted debt financing tools, and asset-backed notes [1]. - The total issuance scale is capped at 40 billion yuan during the effective period of the issuance [1]. - The bond terms will be determined based on the type of instruments issued, with medium-term notes and perpetual medium-term notes having terms exceeding one year, short-term financing bills not exceeding 12 months, and super short-term financing bills not exceeding 9 months [1]. Group 2 - The issuance interest rates will be determined based on market conditions at the time of issuance and negotiated with the lead underwriter [2].

Core Viewpoint - In 2025, the company achieved operating revenue of RMB 24.985 billion, with a pre-tax profit of RMB 2.067 billion, representing a year-on-year growth of 33.57% [1] - The profit attributable to the owners of the parent company from continuing operations was RMB 1.609 billion, an increase of 9.31% year-on-year [1] - The company declared an interim dividend of RMB 0.022 per share and proposed a final dividend of RMB 0.015 per share, totaling a dividend of RMB 0.037 per share for the year [1] Financial Performance - The operating revenue for 2025 was RMB 24.985 billion [1] - The pre-tax profit reached RMB 2.067 billion, marking a 33.57% increase compared to the previous year [1] - The profit attributable to the parent company's owners from continuing operations was RMB 1.609 billion, reflecting a 9.31% year-on-year growth [1] - Basic earnings per share were RMB 0.1214 [1] Dividend Distribution - The company declared an interim dividend of RMB 0.022 per share for 2025 [1] - A final dividend of RMB 0.015 per share is proposed, leading to a total dividend distribution of RMB 0.037 per share for the year [1] Strategic Focus - 2025 is identified as a key year for the company to enhance its shipping genes and release innovative value [1] - The company aims to strengthen its core functions of "production, finance, and investment" and accelerate the development of new productive forces in shipping [1] - The commitment to value creation is emphasized as a means to effectively return to shareholders while pursuing sustainable development [1]